



Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

Keisuke Shigeta¹ · Takeo Kosaka¹ · Hiroshi Hongo¹ · Yoshinori Yanai¹ · Kazuhiro Matsumoto¹ · Shinya Morita¹ · Ryuichi Mizuno¹ · Toshiaki Shinojima¹ · Eiji Kikuchi¹ · Mototsugu Oya¹

Published online: 2 March 2019
© Japan Society of Clinical Oncology 2019

Correction to: International Journal of Clinical Oncology
<https://doi.org/10.1007/s10147-018-01388-5>

In the Original Publication, Tables 2 and 3 have been published with “###” instead of numerical values. Also in Table 2, few entries were inadvertently published in bold. The corrected tables are given in this Correction. The errors have been occurred at Publisher’s end.

The original article has been corrected.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10147-018-01388-5>.

✉ Takeo Kosaka
takenduro@gmail.com

¹ Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

Table 2 Results of univariate and multivariate analysis influencing PFS

	Univariate analysis			Multivariate analysis		
	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
Age						
75 ≥	1.28	0.87–1.82	0.232			
75 <						
PS						
2	1.07	0.68–1.66	0.768			
0,1						
Gleason score						
9 ≥	1.31	0.87–1.63	0.196			
9 <						
Nadir PSA during first ADT (ng/mL)						
≤ 0.2	1.75	1.09–2.43	0.016			
> 0.2						
PSA doubling time (months)						
6 <	1.69	1.05–2.66	0.023			
6 ≥						
Bone involvement						
EOD 2 ≥	1.88	1.27–2.77	0.002	1.84	1.15–2.94	0.011
EOD 2 <						
Visceral metastasis						
Yes	2.50	1.57–3.97	<0.001	1.72	1.04–2.87	0.037
No						
Duration of ADT (months)						
16 <	3.56	2.36–5.36	<0.001	2.54	1.60–4.02	<0.001
16 ≥						
Time to start docetaxel (months)						
12 ≥	1.22	0.81–1.81	0.338			
12 <						
PSA before docetaxel (ng/mL)						
20 ≥	2.27	1.49–3.45	<0.001			
20 <						
Hb (mg/dL)						
10 <	2.16	1.14–4.09	0.001			
10 ≥						
ALP (U/L)						
279 ≥	1.48	0.99–2.20	0.001			
279 <						

PS performance status, *EOD* extent of disease, *ADT* androgen deprivation therapy, *PSA* prostate specific antigen, *Hb* hemoglobin, *ALP* alkaline phosphatase

Table 3 Results of univariate and multivariate analysis influencing CSS

	Univariate analysis			Multivariate analysis		
	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
Age						
75 ≥	1.04	0.59–1.46	0.757	Cont		
75 <						
PS						
2	1.40	0.86–2.27	0.175			
0,1						
Gleason score						
9 ≥	1.27	0.79–1.95	0.335			
9 <						
Nadir PSA during first ADT (ng/mL)						
≤ 0.2	1.99	1.26–3.14	0.003			
> 0.2						
PSA doubling time (months)						
6 <	2.52	1.52–4.16	<0.001			
6 ≥						
Bone involvement						
EOD 2 ≥	2.12	1.36–3.29	0.001			
EOD 2 <						
Visceral metastasis						
Yes	3.32	1.95–5.62	<0.001	2.97	1.73–5.10	<0.001
No						
Duration of ADT (months)						
16 <	3.34	2.13–5.21	<0.001	2.64	1.29–3.61	<0.001
16 ≥						
Time to start docetaxel (months)						
12 ≥	2.05	1.05–3.58	0.001	1.70	1.08–2.67	0.022
12 <						
PSA before docetaxel (ng/mL)						
20 ≥	2.84	1.71–4.71	<0.001	2.15	1.68–4.17	0.004
20 <						
Hb (mg/dL)						
10 <	2.91	1.39–6.13	0.005			
10 ≥						
ALP (U/L)						
279 ≥	1.93	1.24–3.00	0.008			
279 <						

PS performance status, EOD extent of disease, ADT androgen deprivation therapy, PSA prostate-specific antigen, Hb hemoglobin, ALP alkaline phosphatase